This theater presentation will review the efficacy and safety of GAZYVA in combination with chlorambucil as shown in CLL11; explore the proposed mechanism of action of GAZYVA; and review the dosing and administration of GAZYVA in previously untreated patients with chronic lymphocytic leukemia.
A Genentech promotional activity in conjunction with ONS:Edge, Inc., a subsidiary of ONS.
This event qualifies for the ONS:Edge Unlock the Levels of Learning contest. Seating is on a first-come, first-served basis. Please plan to arrive early to have the best chance at securing your seat.